A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Derivation of human Biomonitoring Guidance Values for chlorpyrifos using a physiologically based pharmacokinetic and pharmacodynamic model of cholinesterase inhibition
Regulatory toxicology and pharmacology
A number of biomonitoring surveys have been performed for chlorpyrifos (CPF) and its metabolite (3,5,6trichloro-2-pyridinol, TCPy); however, there is no available guidance on how to interpret these data in a health risk assessment context. To address this gap, Biomonitoring Guidance Values (BGVs) are developed using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. The PBPK/PD model is used to predict the impact of age and human variability on the relationship betweendoi:10.1016/j.yrtph.2014.12.013 pmid:25543108 fatcat:43ajp5rabvgxllzyv3kwxedfpu